FREEDOM OF INFORMATION

REF: 2026-30
Subject: Multiple Sclerosis Freedom of Information Request

Dear Sir/Madam,

Thank you for your email dated **12/01/2026** where you requested information about **Multiple Sclerosis Freedom of Information Request.**

The information you requested is enclosed.

Question	Answer
Q1. How many patients who have a current diagnosis of Multiple Sclerosis received treatment in the last six months with any of the following treatment regimens (July 2025 – December 2025)? We do not supply any of the drugs below for MS. Patients are treated by Salford Royal, part of the Northern Care Alliance Foundation Trust	
• Ocrevus (ocrelizumab) IV (300mg/30ml)	0
• Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml)	0
• Kesimpta (ofatumumab)	0
• Briumvi (ublituximab)	0
• Mavenclad (cladribine)	0
• Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic)	0
• Natalizumab (Tysabri and Tyruko)	0
Q1a. Of the patients identified in question one, how many patients received the same treatment in the previous six-month period? (i.e. How many of the same patients received treatment with each treatment regimen in January 2025 to June 2025 AND July 2025 – December 2025?)	
• Ocrevus (ocrelizumab) IV (300mg/30ml)	0
• Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml)	0

• Kesimpta (ofatumumab)	0
• Briumvi (ublituximab)	0
• Mavenclad (cladribine)	0
• Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic)	0
• Natalizumab (Tysabri and Tyruko)	0
Q2. How many patients have received a new diagnosis for Multiple Sclerosis in the latest six-month period (July 2025 – December 2025)?	0
Q2a. Of the patients identified in question two, how many of these patients have received any of the following treatment regimens as their first treatment following their Multiple Sclerosis diagnosis?	
• Ocrevus (ocrelizumab) IV (300mg/30ml)	0
• Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml)	0
• Kesimpta (ofatumumab)	0
• Briumvi (ublituximab)	0
• Mavenclad (cladribine)	0
• Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic)	0
• Natalizumab (Tysabri and Tyruko)	0

If you have any queries or concerns please do not hesitate to contact the Freedom of Information Department. It would be helpful to quote the above reference number in any future communication.

If you are unhappy with the service you have received in relation to your request and wish to make a complaint or request a review of our decision, you should write to The Chief Executive, Bolton NHS Foundation Trust, The Royal Bolton Hospital, Minerva Road, Farnworth, Bolton. BL4 0JR.

If you are not content with the outcome of your complaint you may apply directly to the Information Commissioner. Generally the Information Commissioner cannot make

a decision unless you have exhausted the complaints procedure provided by Bolton NHS Foundation Trust. The Information Commissioner can be contacted at The Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire. SK9 5AF.

The information supplied to you continues to be protected by the Copyright Design and Patents Act 1998. You are free to use it for your own purposes, including any non-commercial research you are doing and for the purposes of news reporting. Any other reuse, for example commercial publication requires the permission of the Trust. You must ensure you gain the Trust permission before reproducing any third party information.

Yours sincerely,

Information Governance Department

Bolton NHS Foundation Trust
01204 390861
FOI@boltonft.nhs.uk
Informatics Building | Opposite N Block | Royal Bolton Hospital

Improving care,
transforming lives...for a better Bolton